HOUSTON, Jan. 17, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that its President and CEO, Peter
L. Hoang, will present a corporate overview at the
upcoming Phacilitate Leaders World & World Stem Cell
Summit 2019 on Wednesday, January 23,
2019.
Presentation Details
Title: Efficacy without Toxicity: A Multi-Antigen,
Non Gene-Modified Therapy That May Address Current CAR-T
Limitations
Date: Wednesday, January 23, 2019
Time: 2:20 p.m. EST
Location: Hyatt Regency, Miami, FL
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. Once infused into patients,
this population of T cells attacks multiple tumor targets and acts
to activate the patient's immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cells, when compared to current engineered CAR-T and
TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly
less toxic, and (iii) are associated with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling therapeutic product profile, as compared
to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase II clinical
trials. In parallel, we are developing a proprietary DNA expression
technology named PolyStart™ that can enhance the ability of the
immune system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us
on Facebook.
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to our non-engineered multi-tumor antigen specific T cell
therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™
program; the effectiveness of these programs or the possible range
of application and potential curative effects and safety in the
treatment of diseases; and, the timing and success of our clinical
trials, as well as multi-tumor antigen specific T cell clinical
trials conducted by our collaborators. Forward-looking statements
are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from
those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-phacilitate-leaders-world--world-stem-cell-summit-2019-300779802.html
SOURCE Marker Therapeutics, Inc.